Please login to the form below

Not currently logged in
Email:
Password:

sunitinib

This page shows the latest sunitinib news and features for those working in and with pharma, biotech and healthcare.

Merck’s Bavencio joins first-line kidney cancer face-off

Merck’s Bavencio joins first-line kidney cancer face-off

39% reduction in progression-free survival (PFS) for the duo versus Pfizer’s Sutent (sunitinib), which has been the reference standard for first-line RCC treatment for a decade, in

Latest news

More from news
Approximately 3 fully matching, plus 74 partially matching documents found.

Latest Intelligence

  • Accelerating innovation Accelerating innovation

    standard of care - Pfizer’s Sutent (sunitinib). ... We beat, if you will, the standard of care, ”said Alexandre, adding: “We are superior to sunitinib, which has been on the market for 10 years.”The study also showed evidence

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest from PMHub

  • CABOSUN trial of cabozantinib – could it change how we treat frontline renal-cell carcinoma?

    In the CABOSUN trial, cabozantinib was compared to sunitinib in treatment naive poor and intermediate risk renal-cell carcinoma (RCC) patients. ... Summary/transcript. In the  CABOSUN trial, cabozantinib was compared to sunitinib in treatment naive poor

  • Oncology drugs under AMNOG

    Pfizer’ s Inlyta (axitinib) was approved in kidney cancer for patients pre-treated with either another targeted therapy, Sutent (sunitinib), or with older drugs called cytokines. ... Consistent with EMA market authorisations for other kidney cancer

More from PMHub
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Conversis

Conversis is a translation company specialising in translation and localisation for the Life Science and Pharmaceutical industry, with particular focus...

Latest intelligence

EU
Innovation in merger control and the impact on the pharmaceutical sector
Is focusing on pipeline products enough to assess regulatory risks?...
Nudge-nudge, think-think
Chris Ross examines the personal complexities of human behaviour – and explains why fun, emotion and peer endorsement could be key to designing effective behavioural change programmes...
Peoples Award
Quality in Care Diabetes 2018: the best in innovative diabetes care
Awards highlight new evidence-based approaches to improving care...

Infographics